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Summary To date there are few studies that have
investigated bone mineral density (BMD) and mark-
ers of bone metabolism in patients with thalassemia
minor form. None of the previous trials presented
bone structure analysis in the patient populations.
We present the case of a 24-year-old Turkish woman
with heterozygous beta and alpha thalassemia who
sustained a low-trauma fracture of the inferior pubic
ramus. Despite normal markers of bone metabolism,
the dual X-ray absorptiometry (DXA) showed de-
creased areal bone mineral density. Furthermore,
severely reduced bone structure parameters and re-
duced volumetric bone mineral density was assessed
by high-resolution peripheral quantitative computed
tomography (HR-pQCT). Due to these diagnostic
findings at time of peak bone mass, an osteoanabolic
therapy with teriparatide for 24 months was initiated.
The findings concerning BMD and bone structure in
this patient can be seen as caused by the beta and
alpha thalassemia.
Keywords Bone microarchitecture · HR-pQCT · Thal-
assemia
Introduction
Thalassemias name a group of hereditary diseases of
hemoglobin synthesis due to a defect in production
of one or more of the globin chains of hemoglobin
[1]. In more severe forms of thalassemia, ineffective
erythropoiesis necessitates transfusion therapy [2].
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Reduction in bone mineral density (BMD), increased
fractures, deformity and chronic bone pain are well
known problems in patients with beta thalassemia
major [3–6]. To date there are few studies that have
investigated BMD and markers of bone metabolism
in patients with thalassemia minor [7, 8]. None of the
previous trials demonstrated bone structure analysis
in these patients. We present the case of a patient with
bone structure deterioration and a low-trauma frac-
ture with heterozygous beta and alpha thalassemia as
underlying diseases.
Case report
A 24-year-old Turkish woman with known non-trans-
fusion dependent thalassemia was admitted to a spe-
cialized trauma center due to an undisplaced low-
traumatic fracture of the inferior pubic ramus on
the right side. The trauma was sustained when the
patient was walking downstairs. First treatment in-
volved an analgesic therapy, anticoagulation therapy
and early mobilization with progress in weight-bear-
ing strength.
To better understand the cause of the fracture the
patient was admitted to a specialized bone center.
The patient’s medical history revealed no signs of sec-
ondary osteoporosis or endocrinological disorders.
The family anamneses further revealed beta thal-
assemia of both the patient’s mother and her grand-
mother with no fractures in their respective medical
histories. Sex hormones as well as gonadotropin
levels were clarified before admission to the bone
center and were within normal range. She neither
had received any chelation therapy nor any hormone
supplementation. The patient had no births and
her menstrual cycle was normal and regular. The
hemoglobin electrophoreses test as well as genetic
testing for thalassemia was conducted. The results
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showed that the patient is heterozygous for both beta
thalassemia and alpha thalassemia (-α3.7/aa deletion
mutation).
On clinical examination, a reduced BMI of
15.2 kg/m2 (weight 42 kg; height 166 cm) was ob-
served. Due to a transient depressive period the
patient lost 6 kg (from BMI 17.4 to 15.2 kg/m2) and re-
gained weight again after several months. Psychiatric
and dietetic examinations investigating a possible
eating disorder did not show any indications of dis-
eases such as anorexia and bulimia. Furthermore,
the investigations demonstrated a well-balanced and
calcium-rich dietary behavior.
Laboratory values
Laboratory investigations (fasting, before 10 am)
demonstrated high levels of erythrocytes and iron
with reduced values of hemoglobin, MCV, MCH,
MCHC and 25-hydroxyvitamin D. Serum values re-
flecting bone metabolism including procollagen
aminoterminal propeptide type I (PINP, osteoblast
activity), calcium, phosphate, intact parathyroid hor-
mone (iPTH), type-1 collagen crosslinked C-telopep-
tide (CTX, osteoclast activity) levels were all in normal
range (Table 1).
Areal BMD, volumetric BMD and bone
microarchitecture
A dual-energy x-ray absorptiometry (DXA) bone den-
sitometry revealed a Z-score of less than –2 reflecting
a diminished age-adjusted BMD (see Table 1). High-
resolution peripheral quantitative computed tomog-
raphy (HR-pQCT, Scanco, Bruettisellen, Switzerland)
was performed according to the manufacturer’s rec-
ommendations on calibration and scanning proce-
dures. With an in vivo resolution of 82 μm, HR-pQCT
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Table 1 Laboratory values, dual X-rayabsorptiometry and
high-resolutionperipheral quantitative computed tomogra-
phy (HR-pQCT)measurement results. HR-pQCTmeasure-
mentsare incomparisontoahealthycontrolpopulation [13].
Valuesout of normal rangearebold.
Parameters (unit) Value Reference range
Laboratory values
RBC (1012/l) 5.78 4.2–5.4
Hemoglobin (g/dl) 11.1 12–16
Hematocrit (%) 37.0 37–47
MCV (fl) 64.0 80–99
MCH (pg) 19.3 26.0–34.0
MCHC (g/dl) 30.2 32.0–36.0
RDW (%) 17.2 10.0–18.0
Platelets (109/l) 214 150–370
Total serum iron (µg/dl) 33.0 37.0–145.0
Ferritin (ng/ml) 13.0 5–204
TSH (μU/ml) 1.70 0.40–4.00
Calcium (mmol/l) 2.51 2.10–2.58
Phospate (mmol/l) 1.17 0.60–1.55
PTH (pg/ml) 16.9 14.8–83.1


















HR-pQCT (tibia) Healthy controls; median
(interquartile range) [13]
Total BMD (mgHA/cm3) 137.7 305.3 (270.2, 347.3)
Trabecular BMD (mgHA/cm3) 39.40 169.3 (155.0, 200.7)
Cortical BMD (mgHA/cm3) 885.3 874.9 (832.0, 902.7)
BV/TV 0.033 0.141 (0.130, 0.170)
Tb.N (l/mm) 0.650 1.760 (1.590, 2.080)
Tb.Th (mm) 0.050 0.081 (0.074, 0.087)
Tb.1/N.SD (mm) 1.606 0.221 (0.170, 0.242)
Cortical thickness (mm) 0.650 1.130 (0.990, 1.410)
HR-pQCT (radius)
Total BMD (mgHA/cm3) 297.3 325.7 (291.4, 386.3)
Trabecular BMD (mgHA/cm3) 86.30 160.4 (149.2, 190.0)
Cortical BMD (mgHA/cm3) 929.1 879.5 (849.5, 903.4)
BV/TV 0.072 0.129 (0.122, 0.158)
Table 1 (continued)
Parameters (unit) Value Reference range
Tb.N (l/mm) 1.350 1.920 (1.760, 2.230)
Tb.Th (mm) 0.053 0.075 (0.065, 0.086)
Tb.1/N.SD (mm) 0.319 0.186 (0.158, 0.210)
Cortical thickness (mm) 0.790 0.775 (0.685, 0.878)
RBC red blood cell count, MCV mean corpuscular volume, MCH mean
corpuscular hemoglobin, MCHC mean corpuscular hemoglobin concentra-
tion, RDW red cell distribution width, TSH thyroid-stimulating hormone,
PTH parathyroid hormone, BMD bone mineral density, DXA dual energy
X-ray absorptiometry, BV/TV trabecular bone volume, Tb.N number of
trabeculae, Tb.Th trabecular thickness, Tb.1/N.SD inhomogeneity of the
trabecular network
was used to noninvasively assess volumetric bone
mineral density and bone microarchitecture at the
distal tibia and ultradistal radius. At the tibia (Fig. 1)
normal cortical vBMD but very low total vBMD and
trabecular vBMD were observed. The trabecular bone
volume (BV/TV), number of trabeculae (Tb.N) and
the trabecular thickness (Tb.Th) were also decreased.
In addition, a high level of inhomogeneity of trabecu-
lae was shown by this measurement. Additionally, the
cortical thickness was decreased (Table 1).
At the radius (Fig. 2) as a non-weight-bearing bone
site, similar alterations in trabecular bone were ob-
served. In contrast the cortical vBMD was slightly in-
creased and cortical thickness as well as total vBMD
were within normal range (Table 1).
Due to 25-hydroxyvitamin D insufficiency and the
deterioration of bone microarchitecture in conjunc-
tion with a fragility fracture, a supplementation with
cholecalciferol and calcium as well as a primary os-
teoanabolic treatment with teriparatide was initiated.
After 9 months of osteoanabolic therapy a combina-
tion with denosumab as an antiresorptive treatment
is planned. Close follow-up and aftercare programs
were arranged on the patient’s behalf. The patient
was informed that data concerning the case would be
submitted for publication and she provided written
consent.
Discussion
We report on a young woman with a genetically
proven heterozygous form of beta and alpha thal-
assemia who had sustained a low-trauma fracture of
the inferior pubic ramus. Among normal markers of
bone metabolism, significantly decreased values of
trabecular volumetric BMD and clearly reduced bone
microarchitecture at the time point of peak bone mass
were found.
A number of genetic and acquired factors that af-
fect bone density in patients with thalassemia have
already been detailed [6]. Toumba et al. describe
the mechanism of pathogenesis in thalassemia major
as multifactorial. Lack of sex steroids and impaired
growth hormone in thalassemic patients due to pitu-
itary damage, as well as other endocrine complica-
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tions such as hypoparathyroidism and vitamin D defi-
ciency contribute to failure of achieving optimal peak
bone mass [4, 5]. In more severe forms, thalassemia
leads to ineffective erythropoiesis and requires trans-
fusion therapy. Chronic treatment with transfusions
can result in severe iron overload in multiple organs.
Subsequently, iron toxicity and other factors such
as bone marrow expansion, hypogonadism and in-
creased bone turnover are some of the many causes
that are associated with BMD decrease. Patients with
transfusion-dependent thalassemia have a significant
decrease in BMD at the femoral neck and the total
body. However, high hemoglobin, as aspired to, is
attended by an increase in lumbar spine in these
patients [3].
Persons with thalassemia minor (heterozygote
form) are usually symptomless, but the peripheral
blood picture reveals minimal anemia and microcy-
tosis. However, thalassemia minor was also described
to be a risk factor for osteoporosis resulting in low
BMD [8].
Another study reported that in vivo neutron activa-
tion analysis to measure hand-bone phosphorus, sin-
gle-photon absorptiometry to measure forearm bone
mineral content and DXA to measure spinal BMD did
not show any significant differences between a thal-
assemia minor group and a healthy control group. An
investigation concerning markers of bone metabolism
did not show any differences between thalassemia and
healthy subjects, as has been found in our patient [7].
Currently, there are no reported investigations regard-
ing bone architecture/microstructure in thalassemia.
Whereas our patient does not suffer from any eat-
ing disorder such as bulimia and anorexia, she had
a low BMI. Previous studies showed that low BMI can
be a risk factor especially for low trauma hip fractures,
but is not associated with lower leg fractures and dis-
tal forearm fractures [9]. Furthermore the severe al-
terations as shown in HR-pQCT cannot be solely ex-
plained by low body weight.
Because of the young age of the patient at the time
point close to the peak bone mass and the severe
deteriorations of trabecular bone microstructure in
conjunction with a fragility fracture, an osteoanabolic
treatment with teriparatide (TPTD) was initiated to
stimulate osteoblast activation and to immediately
increase bone formation. We will administer—based
on the medical history and the non-invasive find-
ings— a combination therapy with an antiresorptive
drug after 9 months of ongoing TPTD monotherapy to
achieve a reopening of the anabolic window in order
to optimize the anabolic effects of TPTD treatment
[10, 11].
Due to the patient’s young age and the advanta-
geous results concerning BMD and bone microar-
chitecture in previously mentioned combination
therapy studies, we propose to initiate denosumab
(60 mg every 6 months subcutaneously) as an an-
ticatabolic therapeutic agent after 9 months of teri-
paratide monotherapy to maximize bone formation
and secondary mineralization [12].
In conclusion, we report on a young patient
with a heterozygous beta and alpha thalassemia
and a low BMI, who had sustained a fragility frac-
ture. Despite normal markers of bone metabolism,
highly decreased values of trabecular volumetric BMD
and massively reduced bone microarchitecture were
found. Based on our findings, alterations in bone mi-
croarchitecture and consecutively increased fragility
fracture risk should be taken into account in het-
erozygous beta and alpha thalassemia patients with
or without a low BMI.
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